MetaVia Inc. (MTVA) Reports 68.1% Placebo-Adjusted Liver-Fat Reduction

MetaVia (MTVA) reported interim Phase 1 data for DA-1726, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. The company plans to start a Phase 2 study in H2 2027. Full Phase 1 data is expected in Q1 2027.

Original reporting
Published Nov 13, 2026, 1:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MetaVia Inc. (MTVA) Reports 68.1% Placebo-Adjusted Liver-Fat Reduction — source image
Decision brief

The 30-second read

$MTVABullishMed
01

Why it matters

The data provides a tangible milestone for the company's pipeline, potentially influencing valuation and investor sentiment.

02

Market read

First‑time disclosure of promising Phase 1 results could trigger short‑term price movement and affect sector sentiment.

03

What to watch

No safety data disclosed; regulatory timeline remains uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

MetaVia Inc. released interim Phase 1 results for its candidate DA‑1726 targeting non‑alcoholic fatty liver disease.

Company-level read

Ticker impact

$MTVABullishMedium confidence
Context

Interim Phase 1 data shows 68.1% placebo-adjusted liver‑fat reduction and 13.5% weight loss.

Expected impact

likely upward pressure as investors price in a promising clinical readout.

Evidence & confidence

Phase 1 results are encouraging but still early; market may react modestly until Phase 2 data.

Market effects

May boost interest in the metabolic‑disease biotech sector.

Limited to US‑listed biotech investors.

Modest; primarily affects niche biotech investors.

Counterpoint

Early data may be over‑hyped; Phase 2 could fail to replicate results.

Key entities

  • MetaVia Inc.

    Biotech firm developing DA‑1726 for liver‑fat reduction.

Related articles

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 ​ Statistically Significant Increase in Liver and Circulating FGF21 Expression ​ Greater Glucose Lowering and Comparable Weig

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) presented preclinical data at ObesityWeek 2026, showing its drug DA-1726 increased liver FGF21 expression and achieved weight loss comparable to retatrutide with less food intake suppression. The company plans to start a Phase 2 study for MetALD and ALD in late 2027. DA-1726 demonstrated greater glucose lowering and favorable lipid effects. According to MetaVia, the results support DA-1726's potential in liver-related cardiometabolic diseases.

$MTVAMed

MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ ​ ​ MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update ​ Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD ​ Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Le

$MTVAMedAI 8/10

MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Inc. (MTVA) reported Q3 2026 financial results, highlighting positive interim data from its Phase 1 Part 3B study of DA-1726, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. The company plans to initiate a Phase 2 study in 2027. MetaVia also appointed Sarah Browne, M.D., as Chief Medical Officer. R&D expenses increased to $2.6M for Q3 2026, up from $1.9M in Q3 2025, driven by DA-1726 development.